43,758 Shares in Takeda Pharmaceutical Co. $TAK Bought by SG Trading Solutions LLC

Posted by Stanley Muller on Jun 19th, 2026

SG Trading Solutions LLC bought a new position in Takeda Pharmaceutical Co. (NYSE:TAK – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 43,758 shares of the company’s stock, valued at approximately $682,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Takeda Pharmaceutical by 100.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after acquiring an additional 2,854,069 shares during the period. UBS Group AG increased its holdings in shares of Takeda Pharmaceutical by 46.4% in the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after acquiring an additional 1,869,323 shares during the period. Qube Research & Technologies Ltd increased its holdings in shares of Takeda Pharmaceutical by 407.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after acquiring an additional 1,426,184 shares during the period. Van ECK Associates Corp lifted its position in Takeda Pharmaceutical by 98.4% in the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after purchasing an additional 1,143,117 shares during the last quarter. Finally, Voloridge Investment Management LLC lifted its position in Takeda Pharmaceutical by 1,070.7% in the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after purchasing an additional 880,289 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK opened at $15.63 on Friday. Takeda Pharmaceutical Co. has a fifty-two week low of $12.99 and a fifty-two week high of $18.90. The firm’s 50-day simple moving average is $16.49 and its 200 day simple moving average is $16.75. The company has a quick ratio of 0.70, a current ratio of 1.27 and a debt-to-equity ratio of 0.56. The stock has a market cap of $49.76 billion, a P/E ratio of 40.09 and a beta of -0.07.

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The business had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.07%. Equities analysts expect that Takeda Pharmaceutical Co. will post 0.94 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wall Street Zen cut Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research report on Wednesday, April 29th. Finally, Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Takeda Pharmaceutical currently has a consensus rating of “Moderate Buy”.

View Our Latest Research Report on TAK

Takeda Pharmaceutical Profile

(Free Report)

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.